Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma

BACKGROUND: The attenuated, genetically engineered vaccinia virus has been shown to be a promising oncolytic virus for the treatment of patients with solid tumors, through both direct cytotoxic and immune-activating effects. Whereas systemically administered oncolytic viruses can be neutralized by p...

Descripción completa

Detalles Bibliográficos
Autores principales: Chintala, Navin K., Choe, Jennie K., McGee, Erin, Bellis, Rebecca, Saini, Jasmeen K., Banerjee, Srijita, Moreira, Andre L., Zauderer, Marjorie G., Adusumilli, Prasad S., Rusch, Valerie W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977791/
https://www.ncbi.nlm.nih.gov/pubmed/36875061
http://dx.doi.org/10.3389/fimmu.2023.1112960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977791/
https://www.ncbi.nlm.nih.gov/pubmed/36875061
http://dx.doi.org/10.3389/fimmu.2023.1112960

Ejemplares similares